Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JUNIPER: Etrolizumab OLE in Crohn's Disease
NCT02403323Phase 3Terminated
- Sponsor
- Roche
- Start
- Jun 2015
- Primary completion
- Oct 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 33
01
Overview
Phase 3, open-label trial of Etrolizumab in Crohn's disease (2 arms), sponsored by Roche. Primary endpoints: Crohn's Disease Activity Index Remission at 252 weeks, Clinical Remission at 252 weeks and 4 more. Started Jun 2015; status: terminated.
02
Drugs
Etrolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02403323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02403323.